Clinical Study of Herbal Acupoint Application Combined With Paraffin Therapy in the Treatment of Functional Dyspepsia Based on the Warming Therapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2022000038

Enrollment

Unknown

Registered

2022-06-17

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia

Interventions

Herbal acupoint application group:Herbal acupoint application therapy + basic treatment (Omeprazole magnesium enteric coated tablets of 20mg, take orally, once daily for 4 weeks.)

Paraffin therapy group:Paraffin therapy + basic treatment (Omeprazole magnesium enteric coated tablets of 20mg, take orally, once daily for 4 weeks.)

Basic treatment group:Basic treatment (Omeprazole magnesium enteric coated tablets of 20mg, take orally, once daily for 4 weeks.)

Herbal acupoint application combined with paraffin therapy group:Herbal acupoint application combined with paraffin therapy + basic treatment (Omeprazole magnesium enteric coated tablets of 20mg, take

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Individuals who have one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, epigastric burning; (2) Individuals who meet the diagnostic criteria of Rome IV for functional dyspepsia; (3) Individuals who have normal esophagogastroduodenoscopy and Helicobacter pylori detection results within one year; (4) Criteria fulfifilled for the last 3 months with symptom onset at least 6 months before diagnosis; signed the written informed consent form; (5) Aged 18–65 years (either sex); (6) Individuals who did not take antacids, prokinetics, or traditional Chinese medicine within 1 week; (7) Individuals who did not receive acupuncture, herbal acupoint application therapy or other traditional Chinese medicine treatment within 1 week; (8) Individuals who voluntarily agree with a study protocol and sign a written informed consent; (9) Individuals with stable vital signs.

Exclusion criteria

Exclusion criteria: (1) Individuals who combined with liver, gall bladder or pancreatic diseases; (2) Individuals who combined with erosive gastritis, peptic ulcer or gastric tumor; (3) Individuals with unstable vital signs; (4) Individuals who cannot tolerate herbal acupoint application therapy; (5) Legal disabled patients, lactating or pregnant women, or patients unable to correctly express subjective discomfort symptoms; (6) Individuals who have a history of excessive drinking or drug abuse; (7) Individuals who are unable to adhere to treatment.

Design outcomes

Primary

Measure	Time frame
subjective-clinical-assessment of FD symptoms (SCA-FD);	—

Secondary

Measure	Time frame
Hospital Anxiety depression Scale score(HADS);The changes in the mean skin temperature of the Ren channel, Du channel, and the Five Shu Points of the Stomach Meridian, and the Spleen Meridian.;Perceived Stress Scale (PSS);The MOS item short from health survey, SF-36;	—

Countries

China

Contacts

Public ContactXiaochen Yang

Guang'anmen Hospital,China Academy of Chinese Medical Sciences

yangxc822@126.com13146271509

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026